ODAIA, a life science commercialization technology company, netted $25 million in Series B funds to convert its customer pipeline, CEO Philip Poulidis tells Axios exclusively.
Why it matters: Amid an increasing frequency of down-rounds in health tech investment, ODAIA saw an outsider-led up-round and will be cash-flow positive within the next year.
